Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer

Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer

Effective combination therapies to improve the efficacy of BET inhibitors are currently under investigation. Here, the authors examine palbociclib and paclitaxel as two promising candidates for combination therapies with BET inhibition in breast cancer and investigate the dynamics of resistance to t...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jennifer Y. Ge, Shaokun Shu, Mijung Kwon, Bojana Jovanović, Katherine Murphy, Anushree Gulvady, Anne Fassl, Anne Trinh, Yanan Kuang, Grace A. Heavey, Adrienne Luoma, Cloud Paweletz, Aaron R. Thorner, Kai W. Wucherpfennig, Jun Qi, Myles Brown, Piotr Sicinski, Thomas O. McDonald, David Pellman, Franziska Michor, Kornelia Polyak
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/c6750e9707894301940edb49bbf81051
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Effective combination therapies to improve the efficacy of BET inhibitors are currently under investigation. Here, the authors examine palbociclib and paclitaxel as two promising candidates for combination therapies with BET inhibition in breast cancer and investigate the dynamics of resistance to these combinations through DNA barcoding and mathematical modelling.

Ejemplares similares